Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
4 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
12 | 0.7595 | 11.2028910687 | 6.7795 | 8.3965 | 5.4355 | 2136550 | 6.79765099 | CS |
26 | 1.288 | 20.6047032475 | 6.251 | 14.595 | 5.278 | 5705227 | 8.73379905 | CS |
52 | -4.7355 | -38.5799828914 | 12.2745 | 17.3635 | 2.835 | 8452108 | 6.22760471 | CS |
156 | -1374.961 | -99.4546835443 | 1382.5 | 1470 | 2.835 | 3645859 | 94.01655284 | CS |
260 | -2109.961 | -99.6439669421 | 2117.5 | 5862.5 | 2.835 | 2863866 | 367.74873044 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約